WO2000052151A3 - Human secretory proteins - Google Patents

Human secretory proteins Download PDF

Info

Publication number
WO2000052151A3
WO2000052151A3 PCT/US2000/005621 US0005621W WO0052151A3 WO 2000052151 A3 WO2000052151 A3 WO 2000052151A3 US 0005621 W US0005621 W US 0005621W WO 0052151 A3 WO0052151 A3 WO 0052151A3
Authority
WO
WIPO (PCT)
Prior art keywords
secretory proteins
human secretory
hsecp
provides
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/005621
Other languages
French (fr)
Other versions
WO2000052151A2 (en
Inventor
Y Tom Tang
Preeti Lal
Mariah R Baughn
Henry Yue
Janice Au-Young
Dyung Aina M Lu
Yalda Azimzai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals Inc filed Critical Incyte Pharmaceuticals Inc
Priority to AU33939/00A priority Critical patent/AU3393900A/en
Priority to EP00912168A priority patent/EP1165766A2/en
Priority to JP2000602763A priority patent/JP2002537805A/en
Priority to CA002363684A priority patent/CA2363684A1/en
Publication of WO2000052151A2 publication Critical patent/WO2000052151A2/en
Publication of WO2000052151A3 publication Critical patent/WO2000052151A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention provides human secretory proteins (HSECP) and polynucleotides which identify and encode HSECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSECP.
PCT/US2000/005621 1999-03-05 2000-03-03 Human secretory proteins Ceased WO2000052151A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU33939/00A AU3393900A (en) 1999-03-05 2000-03-03 Human secretory proteins
EP00912168A EP1165766A2 (en) 1999-03-05 2000-03-03 Human secretory proteins
JP2000602763A JP2002537805A (en) 1999-03-05 2000-03-03 Human secretory protein
CA002363684A CA2363684A1 (en) 1999-03-05 2000-03-03 Human secretory proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12311799P 1999-03-05 1999-03-05
US60/123,117 1999-03-05

Publications (2)

Publication Number Publication Date
WO2000052151A2 WO2000052151A2 (en) 2000-09-08
WO2000052151A3 true WO2000052151A3 (en) 2001-04-26

Family

ID=22406805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005621 Ceased WO2000052151A2 (en) 1999-03-05 2000-03-03 Human secretory proteins

Country Status (5)

Country Link
EP (1) EP1165766A2 (en)
JP (1) JP2002537805A (en)
AU (1) AU3393900A (en)
CA (1) CA2363684A1 (en)
WO (1) WO2000052151A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7414112B2 (en) 1998-10-08 2008-08-19 Genentech, Inc. Antibodies to PRO1550 polypeptides
EP1666594A3 (en) * 2000-06-02 2006-06-21 Genentech, Inc. Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer
US7335731B2 (en) 2000-07-25 2008-02-26 Genentech, Inc. PRO4332 polypeptides
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6630325B1 (en) * 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
EP1472285A2 (en) * 2001-01-16 2004-11-03 Incyte Genomics, Inc. Secretory molecules
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
US20060121471A1 (en) * 2002-08-14 2006-06-08 L G Life Sciences Ltd. Gene families associated with stomach cancer
US7452968B2 (en) * 2003-01-02 2008-11-18 University Of Southern California Secreted protein factor and cell membrane-bound splice variant
MXPA06003402A (en) * 2003-10-07 2006-06-27 Millennium Pharm Inc MOLECULES OF NUCLEIC ACIDS AND PROTEINS FOR THE IDENTIFICATION, EVALUATION, PREVENTION AND TREATMENT OF CANCER OF OVARY.
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
DK3653221T5 (en) 2015-02-19 2024-08-26 Compugen Ltd ANTI-PVRIG ANTIBODIES AND METHODS OF USE
IL317989A (en) 2016-08-17 2025-02-01 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
JP7348072B2 (en) 2017-06-01 2023-09-20 コンピュジェン リミテッド Triple combination antibody therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030696A2 (en) * 1997-01-13 1998-07-16 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998032853A2 (en) * 1997-01-24 1998-07-30 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998040486A2 (en) * 1997-03-14 1998-09-17 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999022243A1 (en) * 1997-10-24 1999-05-06 Human Genome Sciences, Inc. 148 human secreted proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030696A2 (en) * 1997-01-13 1998-07-16 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998032853A2 (en) * 1997-01-24 1998-07-30 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998040486A2 (en) * 1997-03-14 1998-09-17 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999022243A1 (en) * 1997-10-24 1999-05-06 Human Genome Sciences, Inc. 148 human secreted proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JACOBS K A ET AL: "A genetic selection for isolating cDNAs encoding secreted proteins", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES,GB,ELSEVIER SCIENCE PUBLISHERS, BARKING, vol. 198, no. 1-2, 1 October 1997 (1997-10-01), pages 289 - 296, XP004116069, ISSN: 0378-1119 *
SHIROZU M ET AL: "CHARACTERIZATION OF NOVEL SECRETED AND MEMBRANE PROTEINS ISOLATED BY THE SIGNAL SEQUENCE TRAP METHOD", GENOMICS,US,ACADEMIC PRESS, SAN DIEGO, vol. 37, no. 3, 1 November 1996 (1996-11-01), pages 273 - 280, XP002054773, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
WO2000052151A2 (en) 2000-09-08
CA2363684A1 (en) 2000-09-08
JP2002537805A (en) 2002-11-12
EP1165766A2 (en) 2002-01-02
AU3393900A (en) 2000-09-21

Similar Documents

Publication Publication Date Title
WO2001012662A3 (en) Membrane associated proteins
WO1999061471A3 (en) Human transmembrane proteins
WO2000015793A3 (en) Human gpcr proteins
WO2000018922A3 (en) Human carbohydrate-associated proteins
WO2000021988A3 (en) Human ankyrin family protein
WO2000034477A3 (en) Neuron-associated proteins
WO1999058692A3 (en) Human apoptosis associated proteins
WO2000009709A3 (en) Proteases and associated proteins
WO2001020004A3 (en) Protein phosphatase and kinase proteins
WO2000026245A3 (en) Human membrane transport proteins
WO2000012703A3 (en) Protein transport-associated molecules
WO2000017355A3 (en) Human cytoskeleton associated proteins
WO2000052151A3 (en) Human secretory proteins
WO2001007612A3 (en) Receptors and associated proteins
WO2000014251A3 (en) Human transferase proteins
WO2001005970A3 (en) Gtp-binding protein associated factors
WO2000078953A3 (en) Human transport proteins
WO2000044900A3 (en) Nucleic-acid binding proteins
WO2000028032A3 (en) Human cell surface receptor proteins
WO2001044448A3 (en) Human oxidoreductase proteins
WO1999061614A3 (en) Human socs proteins
WO2000028045A3 (en) Human hydrolase proteins
WO2000065054A3 (en) Human membrane-associated proteins
WO2000008155A3 (en) Human receptor-associated proteins
WO2000078954A3 (en) Human transcriptional regulator proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2363684

Country of ref document: CA

Ref country code: CA

Ref document number: 2363684

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 602763

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000912168

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000912168

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000912168

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)